UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Annals of oncology, 2015-05, Vol.26 (5), p.873-879

2015

Volltextzugriff (PDF)

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Annals of oncology, 2023-12, Vol.34 (12), p.1152-1164

2023

Volltextzugriff (PDF)

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

British journal of cancer, 2013-05, Vol.108 (9), p.1807-1809

2013

Volltextzugriff (PDF)

Second malignancies after breast cancer: the impact of different treatment modalities

British journal of cancer, 2008-03, Vol.98 (5), p.870-874

2008

Volltextzugriff (PDF)

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study

Annals of oncology, 2016-09, Vol.27 (9), p.1725-1732

2016

Volltextzugriff (PDF)

BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy

Breast cancer research and treatment, 2016-10, Vol.159 (3), p.499-511

2016

Volltextzugriff (PDF)

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Annals of oncology, 2015-12, Vol.26 (12), p.2505-2506

2015

Volltextzugriff (PDF)

Prevalence and associated factors of sexual problems after early-stage breast cancer treatment: results of a French exploratory survey

Psycho-oncology (Chichester, England), 2011-08, Vol.20 (8), p.841-850

2011

Volltextzugriff (PDF)

Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: The observational step of the CirCe01 phase III trial

Cancer letters, 2015-05, Vol.360 (2), p.213-218

2015

Volltextzugriff (PDF)

START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)

Annals of oncology, 2018-10, Vol.29, p.viii120-viii120

2018

Volltextzugriff (PDF)

Risks of second malignancies after breast cancer treatment: Long-term results

Cancer radiothérapie, 2017-02, Vol.21 (1), p.10-15

2017

Volltextzugriff (PDF)

Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy

British journal of cancer, 2015-06, Vol.113 (1), p.30-36

2015

Volltextzugriff (PDF)

First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma

British journal of cancer, 2016-05, Vol.114 (11), p.1199-1205

2016

Volltextzugriff (PDF)

EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients

Annals of oncology, 2018-10, Vol.29, p.viii532-viii532

2018

Volltextzugriff (PDF)

Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study

ESMO open, 2022-12, Vol.7 (6), p.100603-100603, Article 100603

2022

Volltextzugriff (PDF)

Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study

Annals of oncology, 2019-04, Vol.30, p.ii48-ii48

2019

Volltextzugriff (PDF)

Can c-myc amplification reliably discriminate postradiation from primary angiosarcoma of the breast?

Cancer radiothérapie, 2015-05, Vol.19 (3), p.168-174

2015

Volltextzugriff (PDF)

Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection

Clinical cancer research, 2006-01, Vol.12 (1), p.62-69

2006

Volltextzugriff (PDF)

Are the asymmetries of the orthostatic posture random?

Revista terapia manual, 2020-07, p.1-6

2020

Volltextzugriff (PDF)

Metastatic NSCLC: Clinical, molecular, and therapeutic factors associated with long-term survival

Respiratory medicine and research, 2019-11, Vol.76, p.38-44

2019

Volltextzugriff (PDF)

Prediction of long-term cumulative incidences based on short-term parametric model for competing risks: application in early breast cancer

Breast cancer research and treatment, 2016-04, Vol.156 (3), p.577-585

2016

Volltextzugriff (PDF)

Concurrent Radiation Therapy and DNA Repair Inhibitor DT01 in Patients With in Transit Melanoma: Results of the First In-Human Phase 1 Study

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.S28-S28

2015

Volltextzugriff (PDF)

Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients

Annals of oncology, 2011-06, Vol.22 (6), p.1458-1459

2011

Volltextzugriff (PDF)

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

Neurology, 2006-01, Vol.66 (1), p.88-92

2006

Volltextzugriff (PDF)

Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data

Revue des maladies respiratoires, 2019-06, Vol.36 (6), p.649

2019

Volltextzugriff (PDF)

1 – 25 von 522

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(468)
Mit Volltextzugriff
(368)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

Second malignancies after breast cancer: the impact of different treatment modalities

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study

BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Prevalence and associated factors of sexual problems after early-stage breast cancer treatment: results of a French exploratory survey

Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: The observational step of the CirCe01 phase III trial

START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)

Risks of second malignancies after breast cancer treatment: Long-term results

Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy

First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma

EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients

Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study

Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study

Can c-myc amplification reliably discriminate postradiation from primary angiosarcoma of the breast?

Meta-analysis of the p53 Mutation Database for Mutant p53 Biological Activity Reveals a Methodologic Bias in Mutation Detection

Are the asymmetries of the orthostatic posture random?

Metastatic NSCLC: Clinical, molecular, and therapeutic factors associated with long-term survival

Prediction of long-term cumulative incidences based on short-term parametric model for competing risks: application in early breast cancer

Concurrent Radiation Therapy and DNA Repair Inhibitor DT01 in Patients With in Transit Melanoma: Results of the First In-Human Phase 1 Study

Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data

Suchergebnisse filtern